Evidence map›Paper›PMID 39730800›Full record

ArticleScientific reports2024

Hemoglobin decrease predicts untoward outcomes better than severity of anemia.

Brigitta Teutsch, Zsolt Abonyi Tóth, Orsolya Ferencz, Nóra Vörhendi, Orsolya Anna Simon, Eszter Boros, Dániel Pálinkás, Levente Frim, Edina Tari, Patrícia Kalló and 11 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Brigitta TeutschInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary. teutschbrigitta@gmail.com.
Zsolt Abonyi TóthCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Orsolya FerenczCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Nóra VörhendiInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Orsolya Anna SimonInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Eszter BorosInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Dániel PálinkásCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Levente FrimInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Edina TariCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Patrícia KallóInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Endre Botond GagyiCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Tamás HusseinInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Szilárd VáncsaInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Vivien VassInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Andrea SzentesiInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Áron VinczeInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Ferenc IzbékiFirst Department of Internal Medicine, Fejér County Szent György University Teaching Hospital, Székesfehérvár, Hungary.
Péter HegyiInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Roland HágendornInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Imre SzabóInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Bálint ErőssInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.

Funding

Nemzeti Kutatási, Fejlesztési és Innovaciós Alap ÚNKP-23-3-II-PTE-1996
6 · The paper itself

Abstract

Patients with gastrointestinal bleeding (GIB) exhibit varying tolerances to acute blood loss. We aimed to investigate the effect of relative Hb decrease (ΔHb%) on GIB outcomes. Participants enrolled in the Hungarian GIB Registry between 2019 and 2022 were analyzed. The primary outcome, defined as a composite endpoint, included in-hospital bleeding-related mortality and the need for urgent intervention. Four groups were created based on the lowest Hb measured during hospitalization (nadirHb), along with four subgroups categorized by ΔHb%. Regardless of the nadirHb, participants with higher ΔHb% had a higher probability of reaching the composite endpoint. A 30-40% ΔHb% decrease to a nadirHb of 80-90 g/L resulted in a similar likelihood of reaching the primary endpoint as a 0-10% ΔHb% to 70-80 g/L or 60-70 g/L, respectively (10% vs. 12%, p = 1.00; 10% vs. 10%, p = 1.00). Our results showed that a higher Hb decrease in GIB is associated with an increased untoward outcome rate even when the lowest hemoglobin exceeds the recommended transfusion thresholds. New randomized controlled trials investigating transfusion thresholds should consider ΔHb% as a potential key variable and risk factor.

Indexed as

AnemiaGastrointestinal HemorrhageHemoglobinsAgedAged, 80 and overBlood TransfusionFemaleHumansMaleMiddle AgedRegistriesRisk FactorsSeverity of Illness IndexHemoglobinsDelta hemoglobinHemoglobin decreaseRestrictiveTransfusion

Identifiers

PMID39730800
PMCPMC11681255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.